BioVie Interview to Air on Bloomberg Television U.S. on the RedChip Money Report®

Rhea-AI Summary

BioVie Inc. (NASDAQ: BIVI) announced an upcoming interview with CEO Cuong Do, set to air on The RedChip Money Report® on June 19, 2021. The interview will cover key milestones in the company’s programs, including a pivotal Phase 3 trial for Alzheimer's involving NE3107 and a Phase 2 study of BIV201 for refractory ascites. BioVie is developing therapies for liver disease and neurological disorders, with BIV201 currently under FDA Fast Track status. Top-line results for BIV201 are anticipated in early 2022.

Positive

• NE3107 acquisition to target neuroinflammation in Alzheimer's and Parkinson's.
• BIV201 granted FDA Fast Track status and evaluated in Phase 2 trials.
• Upcoming interview to provide visibility on company's progress.

Negative

• No significant revenue or clinical trial results announced.
• Market uncertainty concerning the company's ability to raise capital.

SANTA MONICA, Calif., June 17, 2021 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) ("BioVie" or "Company"),a clinical-stage company developing innovative drug therapies for the treatment of liver disease and neurological and neuro-degenerative disorders and certain cancers,, today announced an interview with Cuong Do, CEO of BioVie Inc., will air on The RedChip Money Report® on the Bloomberg Network in the U.S. on this coming Saturday, June 19th, at 7 p.m. local time.

In the exclusive interview, Mr. Do discusses upcoming milestones in the Company’s lead programs, including its pivotal Phase 3 trial in Alzheimer’s with its recently acquired NE3107 asset, and its Phase 2 study of BIV201 in the treatment of refractory ascites.

To view the interview segment, please visit: https://youtu.be/B9u4xqdT6lc

“The RedChip Money Report" delivers insightful commentary on small-cap investing, interviews with Wall Street analysts, financial book reviews, as well as featured interviews with executives of public companies reaching 73M homes across the United States.

About BioVie

BioVie Inc. (NASDAQ: BIVI) is a clinical-stage company developing transformative therapies to overcome unmet medical needs in chronic debilitating conditions. In liver disease, the Company’s Orphan drug candidate BIV201 (continuous infusion terlipressin), with FDA Fast Track status, is being evaluated in a US Phase 2 study for the treatment of refractory ascites with top-line results expected in early 2022. It is administered as a patent-pending liquid formulation. The active agent is approved in about 40 countries for related complications of advanced liver cirrhosis but is not available in the US or Japan. In neuro-degenerative disease, BioVie recently acquired the assets of NeurMedix Inc., including NE3107, an ERK inhibitor that selectively reduces neuroinflammation and insulin resistance. Both are drivers of Alzheimer’s and Parkinson’s diseases. NE3107 and related compounds are globally patented first-in-class small molecules with additional potential to treat certain cancers.

Forward-Looking Statements

This press release contains forward-looking statements, which may be identified by words such as "expect," "look forward to," "anticipate" "intend," "plan," "believe," "seek," "estimate," "will," "project" or words of similar meaning. Although BioVie Inc. believes such forward-looking statements are based on reasonable assumptions, it can give no assurance that its expectations will be attained. Actual results may vary materially from those expressed or implied by the statements herein due to the Company's ability to successfully raise sufficient capital on reasonable terms or at all, available cash on hand and contractual and statutory limitations that could impair our ability to pay future dividends, our ability to complete our clinical trials and to obtain approval for our product candidates, to successfully defend potential future litigation, changes in local or national economic conditions as well as various additional risks, many of which are now unknown and generally out of the Company's control, and which are detailed from time to time in reports filed by the Company with the SEC, including quarterly reports on Form 10-Q, reports on Form 8-K and annual reports on Form 10-K. BioVie Inc. does not undertake any duty to update any statements contained herein (including any forward-looking statements), except as required by law.

Contact:

INVESTOR RELATIONS:
Bruce Mackle
Managing Director
LifeSci Advisors, LLC
bmackle@lifesciadvisors.com

Dave Gentry
CEO
RedChip Companies, Inc.
407-491-4498
www.RedChip.com

FAQ

What is the significance of the upcoming interview featuring BioVie CEO Cuong Do?

The interview will discuss key milestones in BioVie's lead programs, focusing on their Alzheimer’s trial with NE3107 and BIV201 for refractory ascites.

When will the BioVie interview air?

The interview is scheduled to air on June 19, 2021, at 7 p.m. local time on The RedChip Money Report®.

What are the lead programs mentioned by BioVie in the press release?

BioVie's lead programs include a Phase 3 trial for Alzheimer’s with NE3107 and a Phase 2 study of BIV201 for refractory ascites.

What is the status of BIV201 in the treatment of liver disease?

BIV201 is in a Phase 2 study for refractory ascites and has received FDA Fast Track status.

What diseases does BioVie focus on in its research and development?

BioVie focuses on treatments for liver disease, neurological disorders, and certain cancers.